References
- Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019; 4: 934-47. doi: 10.1016/S2468-1253(19)30347-4
- Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010; 17: 194-205. doi: 10.1245/S10434-009-0762-4
- Cemazar M, Sersa G. Recent advances in electrochemotherapy. Bioelectricity 2019; 1: 204-13. doi: 10.1089/BIOE.2019.0028
- Sersa G, Ursic K, Cemazar M, Heller R, Bosnjak M, Campana LG. Biological factors of the tumour response to electrochemotherapy: review of the evidence and a research roadmap. Eur J Surg Oncol 2021. 8: 1836-46. doi: 10.1016/j.ejso.2021.03.229
- Gehl J, Sersa G, Matthiessen LW, Muir T, Soden D, Occhini A, et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 2018; 57: 874-82. doi: 10.1080/0284186X.2018.1454602
- Djokic M, Cemazar M, Popovic P, Kos B, Dezman R, Bosnjak M, et al. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. Eur J Surg Oncol 2018; 44: 651-7. doi: 10.1016/J. EJSO.2018.01.090
- Djokic M, Cemazar M, Bosnjak M, Dezman R, Badovinac D, Miklavcic D, et al. A prospective phase II study evaluating intraoperative electrochemotherapy of hepatocellular carcinoma. Cancers 2020; 12: 1-14. doi: 10.3390/ CANCERS12123778
- Djokic M, Dezman R, Cemazar M, Stabuc M, Petric M, Smid LM, et al. Percutaneous image guided electrochemotherapy of hepatocellular carcinoma: technological advancement. Radiol Oncol 2020; 54: 347-52. doi: 10.2478/RAON-2020-0038
- Edhemovic I, Brecelj E, Cemazar M, Boc N, Trotovsek B, Djokic M, et al. Intraoperative electrochemotherapy of colorectal liver metastases: a prospective phase II study. Eur J Surg Oncol 2020; 46: 1628-33. doi: 10.1016/j. ejso.2020.04.037
- Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, et al. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 2014; 110: 320-7. doi: 10.1002/JSO.23625
- Dežman R, Čemažar M, Serša G, Seliškar A, Erjavec V, Trotovšek B, et al. Safety and feasibility of eElectrochemotherapy of the pancreas in a porcine model. Pancreas 2020; 49: 1168-73. doi: 10.1097/MPA.0000000000001642
- Girelli R, Prejanò S, Cataldo I, Corbo V, Martini L, Scarpa A, et al. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol 2015; 49: 147-54. doi: 10.1515/RAON-2015-0013
- Granata V, Fusco R, Piccirillo M, Palaia R, Petrillo A, Lastoria S, et al. Electrochemotherapy in locally advanced pancreatic cancer: preliminary results. Int J Surg 2015; 18: 230-6. doi: 10.1016/J.IJSU.2015.04.055
- Granata V, Fusco R, Setola SV, Piccirillo M, Leongito M, Palaia R, et al. Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J Gastroenterol 2017; 23: 4767. doi: 10.3748/ WJG.V23.I26.4767
- Casadei R, Ricci C, Ingaldi C, Alberici L, Di Marco M, Guido A, et al. Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results-a single-center experience. Updates Surg 2020; 72: 1089-96. doi: 10.1007/S13304-020-00782-X
- Spiliopoulos S, Zurlo MT, Casella A, Laera L, Surico G, Surgo A, et al. Current status of non-surgical treatment of locally advanced pancreatic cancer. World J Gastrointest Oncol 2021; 13: 2064-75. doi: 10.4251/WJGO.V13. I12.2064
- Tempero MA, Malafa MP, Chair V, Asbun H, Behrman SW, Benson III AB, et al. NCCN Guidelines Version 2.2015, Pancreatic Adenocarcinoma, American Joint Committee on Cancer (AJCC). Available at: https://www2.tri-kobe.org/nccn/guideline/archive/pancreas2015/english/pancreatic.pdf
- Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13. doi: 10.1056/NEJMOA1003825
- Carrato Mena A, Grande Pulido E, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010; 21(Suppl 1): S3-11. doi: 10.1097/01. CAD.0000361534.44052.C5
- Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55. doi: 10.1016/0065-2571(84)90007-4
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8. doi: 10.1006/METH.2001.1262
- D’onofrio M, Beleù A, de Robertis R. Ultrasound-guided percutaneous procedures in pancreatic diseases: new techniques and applications. Eur Radiol Exp 2019; 3: 2. doi: 10.1186/S41747-018-0081-2
- Martin RCG, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 2013; 20(Suppl 3): S443-9. doi: 10.1245/S10434-012-2736-1
- Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M and Barni S. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys 2017; 97: 313-22. doi: 10.1016/j.ijrobp.2016.10.030.
- Campana LG, Miklavčič D, Bertino G, Marconato R, Valpione S, Imarisio I, et al. Electrochemotherapy of superficial tumors - current status: basic principles, operating procedures, shared indications, and emerging applications. Semin Oncol 2019; 46: 173-91. doi: 10.1053/J.SEMINONCOL.2019.04.002
- Bonferoni MC, Rassu G, Gavini E, Sorrenti M, Catenacci L, Torre ML, et al. Electrochemotherapy of deep-seated tumors: state of art and perspectives as possible “EPR effect enhancer” to improve cancer nanomedicine efficacy. Cancers 2021; 13: 4437. doi: 10.3390/CANCERS13174437
- Bosnjak M, Jesenko T, Markelc B, Janzic L, Cemazar M, Sersa G. PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice. Bioelectrochemistry 2021; 140: 107832. doi: 10.1016/J.BIOELECHEM.2021.107832
- Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs 2000; 11: 201-8. doi: 10.1097/00001813-200003000-00008
- Ursic K, Kos S, Kamensek U, Cemazar M, Scancar J, Bucek S, et al. Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma. Bioelectrochemistry 2018; 119:161-71. doi: 10.1016/J.BIOELECHEM.2017.09.009
- Michel O, Kulbacka J, Saczko J, Mączyńska J, Blasiak P, Rossowska J, et al. Electroporation with cisplatin against metastatic pancreatic cancer: in vitro study on human primary cell culture. BioMed Res Int 2018; 2018: 7364539. doi: 10.1155/2018/7364539
- Fernandes P, O’Donovan TR, McKenna SL and Forde PF: Electrochemotherapy causes caspase-independent necrotic-like death in pancreatic cancer cells. Cancers 2019; 11: 1177. doi: 10.3390/cancers11081177
- Dhuriya YK, Sharma D. Necroptosis: a regulated inflammatory mode of cell death. J Neuroinflammation 2018; 15: 199. doi: 10.1186/S12974-018-1235-0.
- Ali MS, Gill KS, Saglio G, Cilloni D, Soden DM, Forde PF. Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells. Bioelectrochemistry 2018; 122: 84-92. doi: 10.1016/J. BIOELECHEM.2018.03.009
- Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, et al. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 2010; 9: 2068-78. doi: 10.1158/1535-7163.MCT-10-0201
- Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, Somcio R, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 2005; 104: 427-38. doi: 10.1002/ CNCR.21145